Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells.pdf (288.64 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-07-22

Llicència de publicació

cc by (c) Catyana Krause, Gabriele et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/175002

Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.17179/excli2019-1415

Resum

The incidence of hepatocellular carcinoma (HCC) keeps rising year by year, and became the second leading cause of cancer-related death. Some studies have found that liraglutide, a GLP-1 analog, may decrease the tumor cells proliferation. Due to this, the aim of this work is to investigate the antiproliferative potential of exenatide, another GLP-1 analog. Cell proliferation was assessed by direct count with Trypan blue dye exclusion. Flow cytometry was used to determinate autophagy and nuclear staining. Morphometric analysis was used to verify senescence and apoptosis. The mechanism that induced cell growth inhibition was analyzed by Western Blot. Treatment with exenatide significantly decreases cell proliferation and increases autophagy, both in relation to control and liraglutide. In addition, mTOR inhibition was greater in cells treated with exenatide. In relation to chronic treatment, exenatide does not allow cellular regrowth by preventing some resistance mechanism that the cells can acquire. These results suggest that exenatide has a potent anti-proliferative activity via mTOR modulation and, among the GLP-1 analogs tested, could be in the future an alternative for HCC treatment.

Matèries

Autofàgia, Càncer de fetge, Medicaments antineoplàstics

Matèries (anglès)

Autophagy, Liver cancer, Antineoplastic agents

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

CATYANA KRAUSE, Gabriele, et al. Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells. EXCLI Journal 2019. vol.18. Vol. 540-548. ISSN 1611-2156. [consulted: 21 of August of 2026]. Available at: https://hdl.handle.net/2445/175002

Exportar metadades

JSON - METS

Compartir registre